home / stock / crvs / crvs quote
Last: | $1.78 |
---|---|
Change Percent: | -1.12% |
Open: | $1.8 |
Close: | $1.78 |
High: | $1.84 |
Low: | $1.77 |
Volume: | 24,068 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.78 | $1.8 | $1.78 | $1.84 | $1.77 | 24,068 | 07-03-2024 |
$1.78 | $1.92 | $1.78 | $1.92 | $1.75 | 131,835 | 07-02-2024 |
$1.85 | $1.81 | $1.85 | $1.89 | $1.7901 | 78,903 | 07-01-2024 |
$1.82 | $1.86 | $1.82 | $1.8799 | $1.79 | 239,076 | 06-28-2024 |
$1.87 | $2 | $1.87 | $2 | $1.85 | 182,692 | 06-27-2024 |
$1.79 | $1.78 | $1.79 | $1.8595 | $1.78 | 50,509 | 06-26-2024 |
$1.78 | $1.84 | $1.78 | $1.9 | $1.78 | 96,939 | 06-25-2024 |
$1.83 | $1.83 | $1.83 | $1.92 | $1.83 | 118,136 | 06-24-2024 |
$1.78 | $1.92 | $1.78 | $1.95 | $1.78 | 513,962 | 06-21-2024 |
$1.91 | $1.88 | $1.91 | $1.96 | $1.85 | 95,577 | 06-20-2024 |
$1.87 | $1.89 | $1.87 | $1.9899 | $1.87 | 114,366 | 06-19-2024 |
$1.87 | $1.89 | $1.87 | $1.9899 | $1.87 | 114,366 | 06-18-2024 |
$1.93 | $2.04 | $1.93 | $2.04 | $1.8 | 573,345 | 06-17-2024 |
$2.04 | $2.1 | $2.04 | $2.2 | $1.98 | 146,683 | 06-14-2024 |
$2.12 | $2.22 | $2.12 | $2.22 | $2 | 149,330 | 06-13-2024 |
$2.07 | $2.17 | $2.07 | $2.195 | $2.05 | 85,405 | 06-12-2024 |
$2.14 | $2.11 | $2.14 | $2.2 | $2.03 | 147,273 | 06-11-2024 |
$2.1 | $2.02 | $2.1 | $2.15 | $1.99 | 197,460 | 06-10-2024 |
$2.03 | $2.05 | $2.03 | $2.2 | $2.01 | 164,972 | 06-07-2024 |
$2.1 | $2.22 | $2.1 | $2.22 | $2 | 154,536 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-o...
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforade...